On the maps, the red bleeds slowly upward. What was once a tight cluster of risk zones hugging the equator, a disease confined to the tropics by temperature as much as anything else, now reaches fingers into the temperate world: the northeastern United States, the suburbs of central Europe, the coastlines of East Asia. By 2100, depending on how much carbon we manage to stop burning, a painful and debilitating tropical infection called chikungunya could become something that doctors in Boston, Berlin, and Tokyo actually need to know about. The maps come from a new modelling study, but the story they tell is older and stranger than the numbers suggest. It begins with a mosquito, a mutation, and a small island in the Indian Ocean.
Chikungunya (the name comes from the Kimakonde language, roughly “to become contorted”) is not one of the glamorous tropical diseases that attracts headlines. It kills, but not in vast numbers. What it does instead is make people exquisitely, memorably miserable: fever, rash, and joint pain so severe that patients hunch and shuffle for weeks, sometimes months, and in some cases years. Around 284,000 disability-adjusted life years are lost to the disease annually, a toll spread largely across countries that global health funding tends to overlook.
The Mosquito That Changed the Rules
For most of its history, chikungunya relied almost entirely on the yellow fever mosquito, Aedes aegypti, a species that thrives in human settlements across the tropics but is genuinely fussy about cold. Below about 12 degrees Celsius, its eggs barely hatch. That fussiness kept chikungunya in a box. Then, during the 2005-2006 outbreak across Reunion, Mauritius, the Comoros and parts of India, which made roughly 266,000 people ill and killed at least 254, scientists detected something alarming: a single mutation in the virus’s genome, labelled E1-A226V, that made it significantly more compatible with a second mosquito entirely. The Asian tiger mosquito, Aedes albopictus, is a different beast. It produces cold-resistant eggs capable of surviving freezing winters in a dormant state, a trick aegypti never mastered, and it has already colonised most of the temperate world. It is in Italy, France, parts of Germany, and large swathes of the United States. It is, in other words, already there. The virus just needed a route in.
That route is now widening. A team of researchers at Zhejiang Chinese Medical University and the Guangzhou Customs Technology Center in China have spent considerable effort mapping precisely how wide it might become.
Their approach involved something more than a single climate model. Using an ensemble of eleven algorithms and 330 models per species, they projected the future ranges of both mosquito vectors under 16 different climate scenarios, then fed those projected ranges into predictions for the virus itself. The logic was hierarchical: climate shapes where the mosquitoes can live, and the mosquitoes in turn determine where the virus can spread. It is a more mechanistically honest approach than simply treating climate as a direct predictor of disease risk, and the numbers that came back were striking. Vectors explained 84% of where chikungunya currently turns up. Aedes albopictus alone accounted for more than 72% of that explanatory power.
“Our results showed that climate change affects chikungunya mainly by changing where its mosquito vectors can live,” said Dr Yang Wu of the Guangzhou Customs Technology Center. “In our study, the Asian tiger mosquito was especially important, explaining more than 70% of the predicted distribution of the virus.”
Where the Lines Are Moving
“Because this mosquito can tolerate cooler conditions better than the yellow fever mosquito, warming may allow it to establish in places that used to be too cold,” Wu added. “When suitable mosquitoes become established, the chance of local chikungunya transmission increases.” The models are fairly consistent on where that establishment is most likely: northeastern North America, north-central Europe, and East Asia keep appearing as high-risk zones regardless of which climate scenario you plug in. At present, 139 countries covering about 21% of the world’s land area already sit in chikungunya’s range. The projections suggest that boundary is going to move, and the populations on the wrong side of it are, by and large, entirely unprepared. Europe got a preview of this in 2007, when a small chikungunya outbreak occurred in northern Italy, the first time the disease had transmitted locally in Europe. The community affected had no immunity and few physicians who recognised the symptoms. It was contained. The question is whether the next one will be.
There are wrinkles in the projections worth paying attention to. Under extreme warming scenarios, tropical areas may actually see chikungunya contract rather than expand. This sounds counterintuitive, but there is a physiological explanation: Aedes aegypti starts to fail above roughly 35°C, and Aedes albopictus above 32°C. Chronically exceed those limits and the mosquito populations collapse, taking the virus’s transmission potential with them. The Sahel region shows this particularly clearly in the models: expansion in the early decades of the century, then contraction as temperatures push past what the vectors can handle. It’s a reminder that climate and disease don’t have a simple linear relationship. The projections for Europe and eastern North America also carry the highest inter-model uncertainty, which is worth flagging honestly: these are ecologically marginal zones for the mosquito, and whether it successfully overwinters in, say, northern Germany depends on winter temperatures that different climate models project quite differently.
The Window for Preparation
Xu noted that 139 countries or regions, accounting for roughly 21% of the world’s land area, currently sit in chikungunya’s risk zone. “But we show that under climate change models, the virus will further expand northward into temperate regions, especially northeastern North America, central Europe, and East Asia.”
The researchers reckon 2040 is roughly the target date by which temperate regions should have monitoring systems and public health infrastructure in place. “The public does not need to panic, but health systems should prepare early,” Xu said. The practical steps are fairly unglamorous: track mosquito populations, train doctors to spot a disease they’ve probably never seen, set up rapid-response plans. None of it is technically difficult. All of it requires acting before the problem arrives rather than after.
What makes chikungunya’s potential expansion particularly awkward is the combination of immunological naivety and healthcare unpreparedness. Populations in Europe and North America have no natural immunity to the virus, no herd protection built up over decades of exposure. If the Asian tiger mosquito is already established in your garden, and the virus arrives via a traveller from a region where it’s endemic, local transmission can begin quickly. The 2014-2015 Americas epidemic, which produced more than 2.9 million suspected or confirmed cases across 45 countries, shows how fast things can escalate once the vector is in place. Most of those affected regions, unlike temperate Europe or North America, at least had some previous encounter with the disease.
The picture that emerges from this research is less a prediction of catastrophe than a fairly specific warning about a closing window. The mosquito is already present across much of the temperate world. The virus is a plane ride away. Climate change is nudging the conditions toward suitability in regions where neither doctors nor health systems are ready. Whether that produces isolated cases or something considerably worse probably depends less on the climate models than on decisions being made, or not made, right now.
https://doi.org/10.3389/fcimb.2026.1808175
Frequently Asked Questions
What is chikungunya and how serious is it?
Chikungunya is a viral disease spread by Aedes mosquitoes that causes fever, rash, and severe joint pain. The joint pain can persist for months or even years in some patients, and the disease costs an estimated 284,000 disability-adjusted life years globally each year. While its death toll is lower than some tropical diseases, the prolonged suffering it causes makes it a significant public health burden.
Why is the Asian tiger mosquito more dangerous for temperate regions than the yellow fever mosquito?
Aedes albopictus, the Asian tiger mosquito, can produce cold-resistant dormant eggs that survive freezing winters, allowing it to establish in temperate climates where Aedes aegypti cannot survive. It has already spread through much of Europe and the United States. A mutation in the chikungunya virus discovered during a 2005-2006 Indian Ocean epidemic made the virus far more compatible with this mosquito, effectively giving it access to a vector already present across the temperate world.
Could extreme climate change actually reduce chikungunya risk in some regions?
Possibly, in certain tropical areas. Both mosquito species have upper thermal limits (around 35°C for Aedes aegypti and 32°C for Aedes albopictus), and prolonged temperatures above those thresholds cause mosquito population collapse. Under the most extreme warming scenarios, some tropical regions may see chikungunya contract rather than expand. However, temperate regions in Europe, North America, and East Asia are projected to face increased risk across most scenarios, and this is where immunological naivety makes the disease most dangerous.
What should health authorities in Europe and North America actually do?
The researchers recommend that temperate regions implement surveillance systems for Aedes mosquito populations and train clinicians to recognise chikungunya before 2040. This means tracking where the Asian tiger mosquito is present, setting up rapid-response outbreak plans, and ensuring doctors can diagnose a disease they currently rarely encounter. The key insight is that acting before a disease arrives is dramatically cheaper and more effective than responding after an outbreak is already underway.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.